Key points are not available for this paper at this time.
Immune checkpoint inhibitors (ICIs) provide modest but unsatisfactory benefits for extensive-stage small cell lung cancer (ES-SCLC). Developing strategies for treating ES-SCLC is critical.
Wang et al. (Wed,) studied this question.